HK1252915A1 - 氯离子通道的靶向表达及其使用方法 - Google Patents

氯离子通道的靶向表达及其使用方法 Download PDF

Info

Publication number
HK1252915A1
HK1252915A1 HK18112264.4A HK18112264A HK1252915A1 HK 1252915 A1 HK1252915 A1 HK 1252915A1 HK 18112264 A HK18112264 A HK 18112264A HK 1252915 A1 HK1252915 A1 HK 1252915A1
Authority
HK
Hong Kong
Prior art keywords
vector
subunit
promoter
nucleic acid
glyr
Prior art date
Application number
HK18112264.4A
Other languages
English (en)
Chinese (zh)
Inventor
G‧R‧托马斯
G‧R‧托馬斯
S‧J‧弗雷泽
S‧J‧弗雷澤
Original Assignee
戈勒尼股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 戈勒尼股份有限公司 filed Critical 戈勒尼股份有限公司
Publication of HK1252915A1 publication Critical patent/HK1252915A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK18112264.4A 2015-10-01 2016-09-28 氯离子通道的靶向表达及其使用方法 HK1252915A1 (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201562235920P 2015-10-01 2015-10-01
US201562235914P 2015-10-01 2015-10-01
US62/235,920 2015-10-01
US62/235,914 2015-10-01
US201662303907P 2016-03-04 2016-03-04
US62/303,907 2016-03-04
US201662378509P 2016-08-23 2016-08-23
US62/378,509 2016-08-23

Publications (1)

Publication Number Publication Date
HK1252915A1 true HK1252915A1 (zh) 2019-06-06

Family

ID=58427328

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18112264.4A HK1252915A1 (zh) 2015-10-01 2016-09-28 氯离子通道的靶向表达及其使用方法

Country Status (11)

Country Link
US (1) US11407812B2 (enExample)
EP (1) EP3355938B1 (enExample)
JP (1) JP7097070B2 (enExample)
KR (2) KR20180072713A (enExample)
CN (1) CN108289965A (enExample)
AU (1) AU2016332847B2 (enExample)
BR (1) BR112018006480A2 (enExample)
CA (1) CA2999279A1 (enExample)
HK (1) HK1252915A1 (enExample)
SG (1) SG10201912703PA (enExample)
WO (1) WO2017058926A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3880179A2 (en) * 2018-11-14 2021-09-22 Flagship Pioneering Innovations V, Inc. Fusosome compositions for cns delivery
CN110679548B (zh) * 2019-10-24 2021-11-30 南方医科大学南方医院 一种自闭症小鼠模型的构建方法
CN111759857A (zh) * 2020-06-30 2020-10-13 宁波市微循环与莨菪类药研究所 Gabrd甲基化靶点在制备抗海洛因复吸药物中的应用
CN115480485B (zh) * 2022-09-14 2024-09-10 南开大学 一种基于数据驱动模型的软镜扭转运动安全控制方法
GB202401492D0 (en) 2024-02-05 2024-03-20 Ucl Business Ltd Chloride channels and uses thereof
CN119331917B (zh) * 2024-10-28 2025-10-17 北京爱思益普生物科技股份有限公司 能够表达GlyR α1/β型GlyR的细胞株及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3644643A (en) * 1969-10-13 1972-02-22 Unimed Inc Method of reducing intraocular pressure using glycine
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US5527703A (en) 1994-05-25 1996-06-18 Merck & Co., Inc. DNA encoding glutamate gated chloride channels
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
US6464986B1 (en) 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
DE60139398D1 (de) * 2000-06-20 2009-09-10 Bionomics Ltd Mutation, welche mit epilepsie assoziiert ist
WO2002066606A2 (en) * 2001-02-16 2002-08-29 Bristol-Myers Squibb Company Polynucleotides encoding a novel glycine receptor alpha subunit expressed in the gastrointestinal tract, hgra4, and splice variant thereof
US20040058313A1 (en) 2002-04-24 2004-03-25 Abreu Marcio Marc Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
US8298818B2 (en) * 2006-04-28 2012-10-30 University Of Florida Research Foundation, Inc. Self-complementary adeno-associated virus having a truncated CMV-chicken β-actin promoter
DK2061891T3 (da) 2006-08-24 2012-07-23 Virovek Inc Ekspression i insektceller af gener med overlappende åbne læserammer, fremgangsmåder og sammensætninger hertil
WO2008143875A1 (en) 2007-05-14 2008-11-27 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Targeted delivery of glycine receptors to excitable cells
EP2058401A1 (en) * 2007-10-05 2009-05-13 Genethon Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
EP2283038A1 (en) * 2008-04-30 2011-02-16 Dublin City University Compositions and methods for expressing in-frame multimeric proteins
JP5775819B2 (ja) * 2008-10-09 2015-09-09 ハワード ヒューズ メディカル インスティチュート 新規なキメラリガンド開口型イオンチャネルおよびその使用方法
US20130184318A1 (en) 2010-04-30 2013-07-18 The Regents Of The University Of California Modulating compliance of trabecular meshwork
WO2012155091A1 (en) 2011-05-11 2012-11-15 Kirax Corporation Package for improved treatment of conditions
EP2877213B1 (en) * 2012-07-25 2020-12-02 The Broad Institute, Inc. Inducible dna binding proteins and genome perturbation tools and applications thereof
EP2692868A1 (en) * 2012-08-02 2014-02-05 Universitat Autònoma De Barcelona Adeno-associated viral (AAV) vectors useful for transducing adipose tissue
WO2014093251A1 (en) * 2012-12-10 2014-06-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Engineered receptors and their use
WO2015106005A1 (en) 2014-01-08 2015-07-16 Circuit Therapeutics, Inc. Method for therapeutic management of ocular hypertension
AU2015237140A1 (en) 2014-03-27 2016-10-13 Circuit Therapeutics, Inc. System and method for therapeutic management of cough
JP2017531652A (ja) 2014-10-06 2017-10-26 アルスロジェン ビー．ブイ．Ａｒｔｈｒｏｇｅｎ Ｂ．Ｖ． Ａａｖに基づく遺伝子治療
KR20200108514A (ko) 2015-09-17 2020-09-21 코다 바이오테라퓨틱스 인코포레이티드 신경 장애를 치료하기 위한 조성물 및 방법
GB2547179A (en) 2015-10-26 2017-08-16 Quethera Ltd Genetic construct
KR20180134846A (ko) 2016-04-21 2018-12-19 바이로베크 인코포레이티드 곤충 세포에서의 aav 생산, 및 이를 위한 방법 및 조성물

Also Published As

Publication number Publication date
AU2016332847B2 (en) 2023-08-10
KR20180072713A (ko) 2018-06-29
JP7097070B2 (ja) 2022-07-07
AU2016332847A1 (en) 2018-04-19
BR112018006480A2 (pt) 2018-10-09
CN108289965A (zh) 2018-07-17
EP3355938A4 (en) 2019-03-06
EP3355938B1 (en) 2024-02-07
EP3355938A1 (en) 2018-08-08
KR20250012721A (ko) 2025-01-24
AU2016332847A2 (en) 2023-08-03
SG10201912703PA (en) 2020-02-27
JP2018533976A (ja) 2018-11-22
US11407812B2 (en) 2022-08-09
US20190010210A1 (en) 2019-01-10
CA2999279A1 (en) 2017-04-06
WO2017058926A1 (en) 2017-04-06

Similar Documents

Publication Publication Date Title
EP3355938B1 (en) Targeted expression of chloride channels and methods of use thereof
JP7097398B2 (ja) ミオシリン（ｍｙｏｃ）緑内障を処置するためのアデノ随伴ウイルスベクター
JP7057281B2 (ja) 眼疾患のための遺伝子療法
MX2014013933A (es) Tratamiento de degeneracion macular relacionada con la edad (amd) usando virus asociados con adeno (aav) sflt-1.
JP6949867B2 (ja) 神経の過剰興奮を治療するための方法および組成物
JP2015503924A (ja) 遺伝子導入のための方法及び組成物
JP2020527335A (ja) 眼疾患のための遺伝子療法
EP3719134B1 (en) Rp2 vectors for treating x-linked retinitis pigmentosa
EP4028027A1 (en) Compositions and methods for treatment of friedreich's ataxia
EP4165193A2 (en) Aav-mediated gene transfer for retinopathy
WO2005079829A2 (en) Method for treating glaucoma
WO2005079836A1 (en) Method for treating glaucoma
US11273227B2 (en) Compositions and methods useful in treating Stargardt's disease and other ocular disorders
US20220273694A1 (en) Compositions and methods for decreasing intraocular pressure
EP4587055A1 (en) Self-complementary aav vectors carrying dominant negative rhoa and methods of use to treat ocular diseases
WO2025175135A1 (en) Modifying neurons to treat or prevent parkinson's disease
KR20220152550A (ko) Nmnat1-연관 망막 변성의 유전자 치료법
Hu et al. 947. Prevention of Skeletal and Cardiac Dysfunction in Dystrophin/Utrophin Double KO Mice by Systemic Delivery of AAV9-Minidystrophin
Albright et al. Elaine M. Tan, Yoshiaki Yamaguchi, Gregory D. Horwitz, 2 Simon Gosgnach, 3 Edward S. Lein, 5 Martyn Goulding, 3
HK40010151A (en) Treatment of amd using aav sflt-1
HK40010151B (en) Treatment of amd using aav sflt-1